Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2013

View Archived Issues

Baxter and Coherus Biosciences to develop and commercialize biosimilar products

NIAID to expand funding for development of bicyclolide from Enanta

Kyowa Hakko Kirin and Ultragenyx collaborate on development of KRN-23

Arsanis raises funds for S. aureus program

Diaxonhit and Boehringer Ingelheim enter oncology target agreement

Treatment with CSL-112 leads to rapid removal of cholesterol from atherosclerotic plaques

Clinical comparison and evaluation of treatment dressings in skin graft donors

PV-10 induces systemic tumor-specific immune responses following intralesional injection

Treatment with herbal preparation STW-5-II prevents DSS-induced ulcerative colitis in vivo

Roche presents novel cathepsin S inhibitors

Researchers at Amgen design novel Na(v)1.7 channel blockers

Parkinson's UK provides grant to study PBT-434

SanBio completes enrollment in stem cell SB-623 trial

Addex Therapeutics reports additional preclinical data on dipraglurant

Amgen prepares new agents that inhibit the GCK-GCKR interaction

Navidea awarded additional grant for NAV-4694 beta-amyloid imaging agent

AstraZeneca begins phase III program for olaparib

BNO-1016 shows efficacy in patients with acute viral rhinosinusitis

Rockwell Medical reports findings from CRUISE-2 study of SFP

Syndax grants Eddingpharm Chinese rights to entinostat

Repligen receives milestone from Pfizer for spinal muscular atrophy program

Sanofi and Pozen sign U.S. commercialization agreement for PA-8140 and PA-32540

Neurodyn acquires Memogain from Galantos Pharma

Theravance reports topline results from phase IIb study of TD-4208 for COPD

Vedolizumab BLA for ulcerative colitis receives FDA priority review status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...